How a small molecule halts the spread of a toxic protein associated with Alzheimer's progression

May 2, 2018 by Elise Lamar, University of California, Los Angeles
Model of cambinol (yellow) binding to nSMase2 shown with electrostatic potential. Blue for positive charge, red for negative charge, and white is for neutral charge. Credit: UCLA Drug Discovery and Translational Lab

Alzheimer's disease destroys brain cells in part by promoting the formation of insoluble clumps that contain a protein called tau. Not only are these "tau aggregates" toxic for the cells that harbor them, but they also invade and destroy neighboring brain cells, or neurons, which speeds the cognitive decline associated with the Alzheimer's.

For those reasons, Alzheimer's researchers have been intensely interested in therapies aimed at either preventing tau aggregation or blocking its spread.

Now, researchers at the UCLA School of Nursing and the department of neurology at the David Geffen School of Medicine at UCLA have reported a promising drug strategy that blocks tau transmission. The study was published online in the journal Biochemical and Biophysical Research Communications.

Using cultured , mouse models and protein structural analysis, the researchers found that a small molecule called cambinol blocks the transfer of tau aggregates from cell to cell. The study could help lay the groundwork for therapies to treat Alzheimer's or other dementias associated with the accumulation of tau.

"Over 200 molecules have been tested as disease-modifying Alzheimer's therapy in , and none has yet attained the holy grail," said Varghese John, a UCLA associate professor of neurology and the study's senior author. "Our paper describes a novel approach to slow Alzheimer's progression by showing it is possible to inhibit propagation of pathologic forms of tau."

John is a member of the UCLA Easton Center for Alzheimer's Disease Research and leads the Drug Discovery and Translational lab.

In healthy people, tau proteins are benign building blocks of a neuron's framework, or cytoskeleton. But in Alzheimer's disease, fall away from the cytoskeleton, become abnormally modified, and then form insoluble "neurofibrillary tangles" that destroy cells. To make matters worse, dying cells encase tau aggregates in lipid vesicles called exosomes, which then bud off and "seed" neighboring tissues, keeping the destructive cycle going.

The researchers conducted several experiments that suggest that cambinol can subvert the "transfer" step by blocking an enzyme called nSMase2, which is essential for catalyzing production of the exosome carriers. In one, the scientists used "donor cells" that harbored tau aggregates derived from postmortem human Alzheimer's specimens and mixed them with tau-free recipient cells.

Without cambinol, the aggregates spread from donors to recipients, mirroring what happens in the brains of people with Alzheimer's. But when treated with cambinol, recipient cells remained tau-free when grown side by side with tau-positive donors, presumably because the drug disabled nSMase2 activity blocking release of the tau-carrying exosomes.

The researchers also observed decreased nSMase2 catalytic activity in the brains of mice that were given cambinol orally. John said the seemingly routine experiment was an essential first step. "Getting molecules into the brain is a big hurdle, because most drugs don't penetrate the blood-brain barrier," he said, referring to the membranes that surround the central nervous system and keep drugs out of it. "Now we know we can treat animals with cambinol to determine its effect on Alzheimer's pathology and progression."

The paper is the first to report on a model of how cambinol switches off nSMase2 catalytic activity at the atomic level, and it provides critical knowledge for medicinal chemists like John to begin designing new drugs based on cambinol that are more potent and efficacious than the molecule itself. That work is already being done in collaboration with Neil Garg, a UCLA professor of chemistry and biochemistry. If the approach is successful in animals, it could be tested in clinical trials.

"Understanding pathways is the first step to new drug targets," said Karen Gylys, a UCLA professor of nursing and a co-author of the study. "With cambinol in hand, we have a useful tool for understanding cellular pathways that enable the spread of tau pathology."

Explore further: New Alzheimer's animal model more closely mimics human disease

More information: Tina Bilousova et al, Suppression of tau propagation using an inhibitor that targets the DK-switch of nSMase2, Biochemical and Biophysical Research Communications (2018). DOI: 10.1016/j.bbrc.2018.03.209

Related Stories

New Alzheimer's animal model more closely mimics human disease

December 4, 2017
By injecting human Alzheimer's disease brain extracts of pathological tau protein (from postmortem donated tissue) into mice with different amounts of amyloid-β (Aβ) plaques in their brains, researchers from the Perelman ...

Researchers reveal unusual chemistry of protein with role in neurodegenerative disorders

July 27, 2017
A common feature of neurodegenerative diseases is the formation of permanent tangles of insoluble proteins in cells. The beta-amyloid plaques found in people with Alzheimer's disease and the inclusion bodies in motor neurons ...

Drug restores cells and memories in Alzheimer's mouse models

July 6, 2017
A new drug can restore memories and connections between brain cells in mice with a model of Alzheimer's disease, a new Yale-led study suggests.

Brain cell death in Alzheimer's linked to structural flaw

July 13, 2016
Researchers have identified a new biological pathway involved in Alzheimer's disease. In experiments using fruit flies, blocking the pathway reduced the death of brain cells, suggesting that interfering with the pathway could ...

Naturally occurring protein fragment found in brain inhibits key enzyme implicated in Alzheimer's

July 29, 2015
For the first time, UCLA researchers have shown that a natural protein fragment produced in the brain can act as an inhibitor of a key enzyme implicated in the onset of Alzheimer's disease, a finding that could lead to the ...

Drug discovery: Alzheimer's and Parkinson's spurred by same enzyme

July 3, 2017
Alzheimer's disease and Parkinson's disease are not the same. They affect different regions of the brain and have distinct genetic and environmental risk factors.

Recommended for you

What really causes Alzheimer's and how might we fix it?

May 23, 2018
There have been a lot of theories about what causes Alzheimer's disease. Many of them have given rise to experimental treatments of one form or another. None of them have worked much better than taking anything you might ...

Study predicts most people with earliest Alzheimer's signs won't develop dementia associated with the disease

May 22, 2018
During the past decade, researchers have identified new ways to detect the earliest biological signs of Alzheimer's disease. These early signs, which are detected by biomarkers, may be present before a person starts to exhibit ...

Moderate to high intensity exercise does not slow cognitive decline in people with dementia

May 16, 2018
Moderate to high intensity exercise does not slow cognitive (mental) impairment in older people with dementia, finds a trial published by The BMJ today.

Mutation discovered to protect against Alzheimer's disease in mice

May 16, 2018
Researchers at the RIKEN Center for Brain Science have discovered a mutation that can protect against Alzheimer's disease in mice. Published in the scientific journal Nature Communications, the study found that a specific ...

Most deprived are nearly twice as likely to develop dementia

May 16, 2018
Older adults in England with fewer financial resources are more likely to develop dementia, according to new UCL research.

Scientists discover a variation of the genome predisposing to Alzheimer's disease

May 15, 2018
An article published in Nature Medicine shows that the inheritance of small changes in DNA alters the expression of the PM20D1 gene and is associated with an increased risk of developing Alzheimer's disease.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.